Europe

InDex Pharma completes patient recruitment in phase III ulcerative colitis study with Kappaproct

Monday, April 8, 2013 10:07 AM

InDex Pharmaceuticals, a Swedish biopharmaceutical company, has completed patient enrollment for its phase III COLLECT study of Kappaproct. The multinational, randomized, double-blind, placebo-controlled study reached the recruitment goal of 120 patients with treatment-refractory ulcerative colitis (UC). InDex is expecting final study results in mid-2014.

More... »

NeuroSearch to update its strategy, reduce staff

Wednesday, March 20, 2013 09:39 AM

NeuroSearch’s transfer of the Huntexil project to Teva Pharmaceutical Industries is now so advanced that the company foresees a significant reduction in the activity level in the near future. Therefore, NeruoSearch will take measures to adjust the organization to the lower activity level and at the same time update its company strategy.

More... »

J&J opens London innovation center

Wednesday, March 13, 2013 02:36 PM

Johnson & Johnson has opened the Johnson & Johnson Innovation center in London, one of four regional hubs being established this year in the world's leading innovation hotspots. A part of Johnson & Johnson Innovation, the goal of the London innovation center is to accelerate the best early stage science in the world and advance the development of new healthcare solutions.

More... »

Progenitor Labs secures $5.8M to progress regenerative medicine platform

Monday, March 11, 2013 11:36 AM

Progenitor Labs, a regenerative medicine company, has raised $5.8 million in seed financing from the U.K. Fund of SR One, GlaxoSmithKline's independent corporate healthcare venture capital fund.

More... »

CoCo Therapeutics created to develop new treatments for Alzheimer’s disease

Friday, March 8, 2013 12:08 PM

King’s College London, The Wellcome Trust and Advent Venture Partners have announced the formation of a new U.K. biotechnology company, CoCo Therapeutics, to progress the research of Professor Jonathan Corcoran into the development of new treatments for Alzheimer’s disease.

More... »

E.U. to fund $187 million in new research on rare diseases

Tuesday, March 5, 2013 03:56 PM

The European Commission, in honor of Rare Disease Day 2013, has announced $187 million of new funding for 26 research projects on rare diseases. The projects will help improve the lives of some of the 30 million Europeans suffering from a rare disease.

More... »

ABPI to introduce new clinical trial transparency measures

Friday, March 1, 2013 02:42 PM

The Association of the British Pharmaceutical Industry (ABPI) will put in place measures to monitor compliance to the clinical trial transparency provisions contained in the ABPI Code of Practice. An independent, third-party service provider will be appointed to undertake this work, and the ABPI will take on the responsibility for reporting non-compliance with trial registration and posting of summary results.

More... »

EMA: Small, medium enterprises see consistent improvement in drug approvals

Friday, March 1, 2013 02:39 PM

Micro, small and medium-sized enterprises (SMEs) registered with the SME office of the European Medicines Agency have seen a consistent improvement in the success rate of their marketing-authorization applications (MAAs) over the past seven years, according to the SME offices’s 2012 annual report.

More... »

Creabilis names Moukheibir to board of directors

Thursday, February 28, 2013 02:33 PM

Creabilis, a late clinical stage European biotechnology company specializing in developing treatments in dermatology, inflammation and pain, has appointed Catherine Moukheibir to its board of directors.

More... »

Sapiens attracts $9.8M for next generation deep brain stimulation therapy

Wednesday, February 27, 2013 10:01 AM

Sapiens Steering Brain Stimulation, an emerging medical technology company developing brain stimulation products, has raised $9.8 million from the Dutch investment group INKEF Capital, in a further extension of their Series A financing round. The proceeds will be used for the development of its Steering Brain Stimulation implant and procedure solutions to treat Parkinson's disease (PD) and other functional brain disorders.

More... »